Leonie M. Mekenkamp

Delft, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Treatment considerations in patients with metastatic pancreatic cancer who did not receive systemic therapy: A population-based study.

Treatment considerations in patients with metastatic pancreatic cancer who did not receive systemic therapy: A population-based study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 18, 2026

Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial.

Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial.

Journal: JAMA network open

Published: March 31, 2026

Flow Enabled Target Capture Halbach-based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients.

Flow Enabled Target Capture Halbach-based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients.

Journal: Molecular oncology

Published: January 19, 2026

Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial.

Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial.

Journal: The Lancet. Oncology

Published: December 13, 2024

Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial.

Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial.

Journal: JAMA surgery

Published: February 14, 2024

Determinants of Physical Activity among Patients with Colorectal Cancer: From Diagnosis to 5 Years after Diagnosis.

Determinants of Physical Activity among Patients with Colorectal Cancer: From Diagnosis to 5 Years after Diagnosis.

Journal: Medicine and science in sports and exercise

Published: December 11, 2023

Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study.

Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: October 12, 2023

Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients.

Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients.

Journal: Frontiers in immunology

Published: March 18, 2022

Physical Activity Is Associated with Improved Overall Survival among Patients with Metastatic Colorectal Cancer.

Physical Activity Is Associated with Improved Overall Survival among Patients with Metastatic Colorectal Cancer.

Journal: Cancers

Published: January 14, 2022

Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study.

Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study.

Journal: International journal of molecular sciences

Published: September 09, 2021

Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX.

Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX.

Journal: Therapeutic advances in medical oncology

Published: February 11, 2021

Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6)

Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6)

Journal: BMC cancer

Published: January 11, 2019

Showing 1-12 of 16

Last Updated: 09/26/2026